Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Vir Biotechnology
Biotech
Vir gains 3 T-cell engagers from Sanofi, lays off 25% of staff
The “strategic restructuring” is designed to push resources into Vir’s hepatitis programs “and focus on the highest near-term value opportunities.”
James Waldron
Aug 2, 2024 6:12am
Vir keeps pressure on Gilead with midphase hepatitis D data
Jun 5, 2024 8:52am
Roche, Vir, Neurocrine & more—Chutes & Ladders
May 31, 2024 8:30am
How Vir found the one: CEO Marianne De Backer
Apr 19, 2024 10:27am
AbbVie names CEO successor—Chutes & Ladders
Feb 23, 2024 9:30am
GSK, Vir end flu drug alliance, removing key piece of $345M pact
Feb 23, 2024 5:10am
